Status:
RECRUITING
Post Splenectomy Infections After Surgery for Peritoneal Malignancies (OPSI)
Lead Sponsor:
Hampshire Hospitals NHS Foundation Trust
Conditions:
Infection;Post Surg Procedure
Peritoneal Cancer
Eligibility:
All Genders
18-79 years
Brief Summary
The spleen is involved in maintaining immunity and plays an important role in the elimination of encapsulated bacteria and parasites. Patients who undergo splenectomy in conjunction with complete CRS ...
Eligibility Criteria
Inclusion Criteria:
- Patients aged >18 and <80 years Patients capable of providing informed consent Patients who have a splenectomy in conjunction with complete cytoreductive surgery (CRS) for any pathology
Exclusion Criteria:
- Patients who are <18 and >80 Patients who do not provide informed consent Patients on immunosuppression therapy
Key Trial Info
Start Date :
March 25 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2031
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT05718726
Start Date
March 25 2021
End Date
February 1 2031
Last Update
November 27 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Peritoneal Malignancy Institute, Hampshire Hospitals NHS Foundation Trust
Basingstoke, Hampshire, United Kingdom, Rg24 9NN